Imran Alibhai, Ph.D.
Chief Executive Officer
David J. Tweardy, M.D.
President, Scientific Advisory Board Member, and Co-Founder
David Tweardy, M.D. is Head of the Division of Internal Medicine at MD Anderson Cancer Center and a physician-scientist recognized for his contributions to our understanding of the biochemistry and molecular and cellular biology of signal transducer and activator of transcription (STAT) 3, as well as its contribution to inflammation, fibrosis, and oncogenesis. His group claims several firsts in the STAT3 field, including the identification, molecular cloning, and full characterization of the β isoform of human STAT3, identifying the contribution of STAT3 to human oncogenesis, and discovering competitive small-molecule inhibitors of STAT3 through targeting its Src homology (SH) 2 domain. He has obtained $15M in non-dilutive funding to support development of small-molecule STAT3 inhibitors from concept to Phase I testing. Dr. Tweardy is the major inventor of all patents licensed to or owned by Tvardi. Dr. Tweardy received his M.D. at Harvard Medical School and an A.B. in Chemistry from Princeton University.
Ronald A. DePinho, M.D.
Chairman of Board of Directors, Scientific Advisory Board Member, and Co-Founder
Ronald Depinho, M.D. has had a distinguished career in cancer research including his role as President of the University of Texas, MD Anderson Cancer Center. During his tenure as MD Anderson’s president, Dr. DePinho conceived and launched the Cancer Moon Shots Program, maintained MD Anderson’s top ranking, dramatically enhanced its research and training excellence, recruited many world class faculty, and expanded its global network to reach one-third of the human population. His research program has made fundamental contributions to our understanding and treatment of cancer, aging and degenerative disorders. He is a member of the National Academy of Science and National Academy of Medicine and recipient of honorary degrees and many awards including the Ellis Island Medal of Honor and knighthood from Portugal. Dr. DePinho has successfully founded and raised capital for numerous biotech companies including publicly traded Aveo and Karyopharm. He was an advisor for biotech firms, Epizyme and Agios as well as Abbott and GSK. He holds an M.D. from Albert Einstein College of Medicine and a B.S. from Fordham University.
Founder and President, Wetland Partners, LP.
Mr. Hall is founder and president of Wetland Partners, LP., which is primarily engaged in wetland mitigation banking and oil & gas investments. Mr. Hall is also a co-founder of BioMatrix Partners, an investment partnership focused on public and private biotechnology companies, with an emphasis on early-stage opportunities enabled by synthetic biology. Mr. Hall has invested in a wide range of businesses for over 30 years, serving in a variety of leadership capacities. An active member of his community, Mr. Hall has served in multiple leaderships roles with St. Mark’s School of Texas, the Texas Higher Education Coordinating Board, and most recently, a six-year term with the University of Texas System Board of Regents. He is a graduate of the University of Texas at Austin with a Bachelor of Arts in Economics.